Takashi Kojima
YOU?
Author Swipe
View article: Correlations between Amyloid-β Peptide Levels in Aqueous Humor, Retinal Thickness, and Visual Field Loss in Patients with Glaucoma
Correlations between Amyloid-β Peptide Levels in Aqueous Humor, Retinal Thickness, and Visual Field Loss in Patients with Glaucoma Open
Amyloid-β (Aβ) accumulation is a well-established cause of neurotoxicity in the brain and a major factor in Alzheimer's disease. However, its role in ocular neurodegeneration remains unclear. In this prospective study, we evaluated the cor…
View article: Application of LMM-Derived Prompt-Based AIGC in Low-Altitude Drone-Based Concrete Crack Monitoring
Application of LMM-Derived Prompt-Based AIGC in Low-Altitude Drone-Based Concrete Crack Monitoring Open
In recent years, large multimodal models (LMMs), such as ChatGPT 4o and DeepSeek R1—artificial intelligence systems capable of multimodal (e.g., image and text) human–computer interaction—have gained traction in industrial and civil engine…
View article: SiO2-supported niobia catalyst with optimized acid concentration prepared via organic additive-assisted impregnation protocol for the vapor-phase aldol condensation of butanal
SiO2-supported niobia catalyst with optimized acid concentration prepared via organic additive-assisted impregnation protocol for the vapor-phase aldol condensation of butanal Open
View article: 398P Efficacy and safety of radiation therapy alone in patients with stage II/III esophageal squamous cell carcinoma intolerant of chemotherapy and surgery: A multi-center retrospective study
398P Efficacy and safety of radiation therapy alone in patients with stage II/III esophageal squamous cell carcinoma intolerant of chemotherapy and surgery: A multi-center retrospective study Open
View article: Generation of highly dispersed Cu nanoparticles on SiO2 support using impregnation protocol assisted with sugar alcohol for selective vapor-phase hydrogenation of citral
Generation of highly dispersed Cu nanoparticles on SiO2 support using impregnation protocol assisted with sugar alcohol for selective vapor-phase hydrogenation of citral Open
The impregnation protocol, assisted with sugar alcohol such as sorbitol, effectively generated SiO2-supported Cu (Cu/SiO2) containing highly dispersed Cu nanoparticles, i.e. high Cu surface area. The resulting Cu/SiO2 catalyst efficiently …
View article: Promotion effect of Al species on silica-supported cesium oxide catalyst in the vapor-phase dehydration of 1,2-propanediol to propylene oxide
Promotion effect of Al species on silica-supported cesium oxide catalyst in the vapor-phase dehydration of 1,2-propanediol to propylene oxide Open
View article: Improving catalytic activity and stability of ZrO2 and CeO2 in the vapor-phase intramolecular aldol condensation of 2,5-hexanedione to 3-methyl-2-cyclopentenone
Improving catalytic activity and stability of ZrO2 and CeO2 in the vapor-phase intramolecular aldol condensation of 2,5-hexanedione to 3-methyl-2-cyclopentenone Open
View article: Vapor-phase hydrogenation of citronellal over silica-supported copper prepared <i>via</i> organic additive-assisted impregnation protocol
Vapor-phase hydrogenation of citronellal over silica-supported copper prepared <i>via</i> organic additive-assisted impregnation protocol Open
The hydrogenation of citronellal to citronellol proceeded over SiO2-supported copper (Cu/SiO2) catalysts prepared by organic additive-assisted impregnation protocol. Introducing Cu species on SiO2 support reduced the rate of the cyclizatio…
View article: Interchangeability of Cross-Platform Orthophotographic and LiDAR Data in DeepLabV3+-Based Land Cover Classification Method
Interchangeability of Cross-Platform Orthophotographic and LiDAR Data in DeepLabV3+-Based Land Cover Classification Method Open
Riverine environmental information includes important data to collect, and the data collection still requires personnel’s field surveys. These on-site tasks still face significant limitations (i.e., hard or danger to entry). In recent year…
View article: Nivolumab with Definitive Chemoradiotherapy for Oesophageal Squamous Cell Carcinoma: A Phase II Trial (NOBEL Trial)
Nivolumab with Definitive Chemoradiotherapy for Oesophageal Squamous Cell Carcinoma: A Phase II Trial (NOBEL Trial) Open
View article: STUDY ON THE SURVEY OF RIVER SPACE UTILIZATION USING A RIVER MONITORING CAMERA, OBJECT DETECTION, AND A LARGE-SCALE MULTIMODAL MODEL
STUDY ON THE SURVEY OF RIVER SPACE UTILIZATION USING A RIVER MONITORING CAMERA, OBJECT DETECTION, AND A LARGE-SCALE MULTIMODAL MODEL Open
View article: A Multicenter Study on Clinical Outcomes of Simultaneous Implantable Collamer Lens Removal and Phacoemulsification with Intraocular Lens Implantation in Eyes Developing Cataract
A Multicenter Study on Clinical Outcomes of Simultaneous Implantable Collamer Lens Removal and Phacoemulsification with Intraocular Lens Implantation in Eyes Developing Cataract Open
View article: Generating 3D Models for UAV-Based Detection of Riparian PET Plastic Bottle Waste: Integrating Local Social Media and InstantMesh
Generating 3D Models for UAV-Based Detection of Riparian PET Plastic Bottle Waste: Integrating Local Social Media and InstantMesh Open
In recent years, waste pollution has become a severe threat to riparian environments worldwide. Along with the advancement of deep learning (DL) algorithms (i.e., object detection models), related techniques have become useful for practica…
View article: Clinical implementation of simultaneous multiple biomarkers testing for metastatic or recurrent gastroesophageal adenocarcinoma: a single-institutional experience
Clinical implementation of simultaneous multiple biomarkers testing for metastatic or recurrent gastroesophageal adenocarcinoma: a single-institutional experience Open
Background: Evaluating multiple biomarkers including human epidermal growth factor receptor 2 (HER2), mismatch repair (MMR) status, programed death-ligand 1 (PD-L1), and claudin 18.2 (CLDN18.2) is essential for selecting appropriate first-…
View article: <b>Automating Visual Inspection for Underbody Equipment of Railway Vehicles Using On-track Cameras</b>
<b>Automating Visual Inspection for Underbody Equipment of Railway Vehicles Using On-track Cameras</b> Open
The authors developed an imaging system and a diagnosis algorithm for automating visual inspection of underbody equipment of railway vehicles. The developed system consists of a line scan camera, line lights, a laser Doppler velocimeter an…
View article: DEEP LEARNING OF UNDERWATER IMAGES AND TRAINING DATA CRITERIA FOR UNDERSTANDING FEEDING INJURY OF <i>ACANTHOPAGRUS SCHLEGELII</i> IN NORI SEAWEED FARMS
DEEP LEARNING OF UNDERWATER IMAGES AND TRAINING DATA CRITERIA FOR UNDERSTANDING FEEDING INJURY OF <i>ACANTHOPAGRUS SCHLEGELII</i> IN NORI SEAWEED FARMS Open
近年の岡山県の養殖ノリ生産量減少の一因としてクロダイの食害があり,その蝟集状況の効率的な把握に向けて対象種を撮影した水中カメラ画像への深層学習モデルの適用が考えられる.モデルが学習する教師データの質は検出精度を左右するが,自然環境下では不鮮明な画像があり,客観的条件を設けてラベリングすることは困難であった.本研究では不鮮明に写った対象種に対して,近年開発された画像領域分割モデルSAMを活用し,ラベリングの対象基準を設けてクロダイ検出モデルを作成した.また,実海域での計数に際…
View article: Development of the method for estimating wheel load unbalance ratio of railway container cars using image processing
Development of the method for estimating wheel load unbalance ratio of railway container cars using image processing Open
View article: Automated visual inspection for underbody equipment of railway vehicles
Automated visual inspection for underbody equipment of railway vehicles Open
View article: Preparation of porous titania particles via hot water or hydrothermal treatment of porous hydrous titania and their photocatalytic ability
Preparation of porous titania particles via hot water or hydrothermal treatment of porous hydrous titania and their photocatalytic ability Open
The synthesis of porous titania microparticles with high specific surface area and sufficient photocatalytic activity is an important but challenging task. To this aim, micron-sized porous titania particles exhibiting photocatalytic activi…
View article: Figure SF2 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
Figure SF2 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study Open
Patient disposition.
View article: Supplementary Methods SM1 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
Supplementary Methods SM1 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study Open
Supplementary methods including inclusion and exclusion criteria
View article: Data from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
Data from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study Open
Purpose:We conducted a first-in-human, dose-escalation study, to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and activity of TAK-931, a cell division cycle 7 inhibitor, in Japanese patients with advanced solid tu…
View article: Data from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
Data from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study Open
Purpose:We conducted a first-in-human, dose-escalation study, to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and activity of TAK-931, a cell division cycle 7 inhibitor, in Japanese patients with advanced solid tu…
View article: Table ST1 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
Table ST1 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study Open
Summary of best response to treatment for patients in the pharmacodynamic-evaluable population (schedule A).
View article: Figure SF4 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
Figure SF4 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study Open
(A) Best percent change from baseline in tumor size for all patients in schedule A. (B) and (C) computed tomography scans from patients in schedule A at screening (left panels) and 9 weeks post-dose (right panels); (B) patient with duodena…
View article: Figure SF3 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
Figure SF3 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study Open
Mean (+StDev) plasma concentration-time profiles of TAK-931 in patients after: (A) a single dose or (B) multiple doses of TAK-931 at cycle 1, day 1 by schedule (linear scale) in the pharmacokinetic-evaluable population.
View article: Figure SF3 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
Figure SF3 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study Open
Mean (+StDev) plasma concentration-time profiles of TAK-931 in patients after: (A) a single dose or (B) multiple doses of TAK-931 at cycle 1, day 1 by schedule (linear scale) in the pharmacokinetic-evaluable population.
View article: Figure SF1 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
Figure SF1 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study Open
Dosing, PK, and pharmacodynamic sampling schedules.
View article: Table ST2 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
Table ST2 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study Open
Summary of best response to treatment per investigator’s assessment.
View article: Table ST1 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
Table ST1 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study Open
Summary of best response to treatment for patients in the pharmacodynamic-evaluable population (schedule A).